279 results about "Prostate disease" patented technology

A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to the prostate-specific antigen, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to homeopathic technology. In order to obtain the antibodies, the prostate-specific antigen isolated from the prostatic tissues of cattle or prepared synthetically is employed; a mixture of various, mostly centesimal, homeopathic dilutions is used. The method of treating diseases of the urogenital sphere consists in using activated forms of ultra-low doses of antibodies to prostate-specific antigen prepared by multiple consecutive dilutions and exposure to external factors.

The invention discloses a computerized auxiliary diagnosing method for malignant tumor in early stage based on deep learning algorithm. According to the invention, a deep convolution neural network is used to extract the high-level characteristics of an image layer by layer so that the obtained characteristic dimensions become smaller and smaller. To realize the dimension matching between an outputted probability predicting image and a pre-segmented image, the method uses the reverse convolution network to expand the dimensions of the characteristic image so as to obtain a dimension-consistent probability predicting image. The network generated probability predicting image extracts the binarization of the predicting image through the training of a softmax classifier to finally obtain the segmentation result of the prostate tissue. To some extent, the method effectively increases the accuracy and efficiency for doctors to diagnose prostate diseases.

The present invention relates to a method capable of using natural and artificial synthetic isosulfocyanate compound or its derivative to prevent and cure prostatic diseases and skin carcinoma. The internal tests show that various isosulfocyanate compounds or their derivatives can induce prostatic cell II phase drug metabolic detoxication enzyme-glutathione transferase so as to can inhibit the hyperplasia of prostate and inflammation, and can prevent and cure prostatic carcinoma and skin carcinoma.

The invention relates to a Chinese medicinal preparation for treating a prostate disease, which is a medicament prepared from 70 raw material medicaments such as ginseng, deerhorn glue, medicinal indianmulberry root, common curculigo rhizome and the like. The medicament can be prepared into oral liquid, granules, powder, capsules, electuary, tablets or pills. A preparation method of the medicament comprises the following steps of: (1) preparing water extracting solution by the raw material medicaments; (2) preparing oral liquid by the water extracting solution; (3) drying, crushing and sieving the water extracting solution, and taking screening as medicinal extracting powder; and (4) preparing tablets, granules, pills or capsules from the medicinal extracting powder. The preparation method also can comprise the following steps of: (1) crushing and sieving the raw material medicaments, and taking the screening as medicinal powder; (2) disinfecting and sterilizing the medicinal powder to obtain raw powder; and (3) preparing tablets, granules, pills, electuary or capsules from raw powder. The adopted raw material medicaments are common Chinese medicaments, so the Chinese medicinal preparation has the advantages of low manufacturing cost, and nearly no toxic or side effects. The medicament has good curative effects on prostatitis, prostatic hypertrophy and prostatomegaly, and has obvious effect on prostate cancers.

This invention relates, in part, to methods and products for the detection of cancer, such as prostate cancer or multiple myeloma. This invention also relates, in part, to methods and products for the detection of prostate disease, such as benign prostatic hyperplasia (BPH). This invention further relates, in part, to methods and products for the detection of specific glycans in one or more samples, such as, for example, methods whereby specific glycans are detected and their amounts analyzed. Such methods can be used to determine relative ratios and / or threshold values for the specific glycans described herein. The relative ratios and / or threshold values can be used in the methods provided.

This invention describes compositions and methods for use in PSA assays having low functional sensitivity which are useful, for example, in the detection of early stage recurrence of prostate disease following treatment and in the determination of whether patients have early stage biochemical reoccurrence (ES-BCR) or stable disease.

The invention discloses a traditional Chinese medicine preparation for treating prostate disease, frequency of micturition, muscle swelling pain, impotence, prospermia and the like, which is characterized in that the preparation is prepared by the following raw material drugs by weight part: panax notoginseng 5-10, gallnut 10-20, rhubarb 10-15, catechu 10-15, coptis 10-20, scutellaria prepared tag 10-15, dodder 10-15, herba epimedii 10-20, eucommia bark 10-20, rhizome anemarrhenae 10-20, rehmannia glutinosa libosch 10-15, alisma 10-15, cortex moutan 10-15, Tuckahoe 10-15, prepared fleece-flower root 10-15, rhizome polygonati 10-20,rattanpalm 10-20, salvia miltiorrhiza 10-20, Chinese yam 10-20, peach kernel 10-20, safflower 10-20, foeniculum vulgare 5-10, fructus meliae toosendan 5-10, radix linderae 10-15, red paeony root 10-15, boneset 10-15, dandelion 10-30, radix codonopsitis 10-15, sauted Atractylis ovata 10-15, adlay 10-15, fructus amomi 10-15, alisma 10-20, angelica 10-20, leonurus 10-20, dried orange peel 10-20, akebia stem 10-20, plantain seed 10-30, knotgrass 10-30, herba dianthi 10-30, talcum 10-30, gardenia rhubarb 10-30, licorice 10-30, purslane 10-30, officinal magnolia bark 10-30, platycodon root 10-30, motherwort 10-30, self-heal 10-30, eucommia bark 10-15, boxthorn fruit 10-15, Japanese fern spore 10-15, root of rehmannia 10-15, wild celery 10-30, black lotus seed 10-30, fructus alpiniae oxyphyllae 10-30, pepper 10-30, cornu cervi 10-30, hoantchy root 10-30, leek seed 10-20, epimedium 10-20, radix morindae 10-20, phellodendron amurense white paeony root 10-30, radix codonopsitis 10-30, aconite 10-30, radix morindae 10-30, broomrape 10-30, schisandra 10-30, boxthorn fruit 10-30, dodder 10-30, curculigo orchioides 10-30, dogwood 10-30, prepared rhizome of rehmannia 10-30, cynomorium songaricum 10-30, fructus gleditsiae sinensis 10-30,cassia twig 5-10, radix patriniae heterophylla 10-15, ladybell root 10-15, root of glutinous rice 10-15, etc.

The present invention is directed to sensitive and specific methods and kits for the detection of prostate cancer in a patient. The invention uses RT-PCR to detect the expression or change in expression of PSA in epithelial cells enriched from whole blood. The methods and kits on the invention represent a a significant improvement over previous methods of CaP diagnosis. According to one embodiment, prostate epithelial cells are isolated from blood and the RNA subjected to RT-PCR. The resulting cDNA is subjected to traditional PCR amplification with primers able to distinguish between the genomic copy of the gene and the cDNA copy resulting from CaP gene expression. This method provides an assay which is more sensitive, specific and reproducible as compared to conventional methods. Results disclosed herein demonstrate a correlation between the presence of PSA-expressing prostate epithelial cells with cancer recurrence which provides a diagnostic tool for the early detection of prostate disease.

Gene expression data are analyzed using learning machines such as support vector machines (SVM) and ridge regression classifiers to rank genes according to their ability to separate prostate cancer from BPH (benign prostatic hyperplasia) and to distinguish cancer volume. Other tests identify biomarker candidates for distinguishing between tumor (Grade 3 and Grade 4 (G3 / 4)) and normal tissue.

A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS116 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS116-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS116 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.

This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostrate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.

Deuterated dipeptide boric acids or esters thereof, or crystal forms thereof, or pharmaceutically acceptable hydrates or solvates thereof are disclosed. The general structure of the compounds is shown as a formula (a) in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, deuterium or halogens, or C1-C4 alkyl one or a plurality of or all hydrogen atoms of which are deuterated; and at least one of the R1, the R2, the R3, the R4, the R5 and the R6 is deuterated or deuterium. The compounds can effectively inhibit proteasomes and effectively treat or prevent cancer, cardiovascular disease, inflammation, immune disease, nephropathy, vasculogenesis or prostate disease.

The invention discloses a health-care food for males and a preparation method thereof. The health-care food is prepared according to a traditional Chinese medicine theory and the respective health-care efficacies and characteristics of maca, cistanche and liquorice; maca has the efficacies of resisting fatigues, improving sexual functions, increasing the number of sperms, improving the quality of the sperms, reducing benign prostatic hyperplasia, enhancing fertility and the like; traditional Chinese medicine cistanche has the efficacies of benefiting essence and blood, tonifying the kidney and reinforcing yang as well as lubricating intestines and smoothing bowels and can have health-care effects on kidney deficiency and impotence, spermatorrhea and premature ejaculation, coldness and pain of a waist and knees and the like; liquorice is a tonifying Chinese herbal medicine and can coordinate drug properties as well as tonify spleen and benefit qi. By virtue of a nanotechnology, the bioavailability of bioactive molecules in maca, cistanche and liquorice is improved; by virtue of fine processing, maca, cistanche and liquorice are prepared into the health-care food for males; the health-care food is safe and effective, nontoxic and harmless, and has synergistic effects on improvement of sexual function, enhancement of fertility, regulation of internal secretion, reduction of prostate diseases and improvement of the immunologic function of an organism.

The invention belongs to the field of prostate disease medical equipment and particularly relates to a method for improving a prostate tumor MRI (Magnetic Resonance Imaging) image identification rate based on a CAD (Computer-Aided Diagnosis) system. The method comprises the following steps: (1) collecting an MRI image of a prostate patient; (2) extracting MRI prostate tumor ROI region features; (3) carrying out feature-grade fusion on the ROI region features; and (4) identifying the fused features by classification through taking a neural network as a classification device. By virtue of the method, the capabilities of identifying the prostate benign and malignant tumors are at least improved by 10%, and the method has active meanings on the CAD of the MRI prostate tumors.

The present invention relates to a medical device for treating prostate diseases by using near-infrared LEDs (light emitting diodes), and more particularly to a medical device for treating prostate diseases in which a probe having installed therein near-infrared LEDs and a vibrator is constructed to be inserted into the rectum to radiate near-infrared rays to the prostate from a position closest to the prostate and render a direct physical massage function to the prostate, thereby effectively treating prostate-related diseases. Also, the present invention relates to a pad mechanism supplementing the probe mechanism, being brought into close contact with the perineal region to radiate red visible rays and transmit vibration to the organs around the prostate thereby curing the natures of diseases in the organs around the prostate, and a disposable probe condom used in a state in which it is worn over the probe mechanism.

Methods and apparatus are provided for improved administration of brachytherapy in the treatment of prostate disease. More particularly, a prostate visualization device is provided comprising a catheter coupled to at least one deployable member at the distal end of the catheter. The deployable member is preferably manufactured from a shape memory alloy having a petal-shaped configuration suitable for engaging and defining the proximal region of a patient's bladder. The deployable member may comprise tubing filled with air or other radiopaque agents to facilitate ultrasonic imaging of the deployable members near the bladder / prostate junction.

The invention discloses a liquid-phase chip method for detecting a PCA3 gene and a PSA gene and a diagnostic reagent kit thereof. A primer and a probe are designed for mRNA of the PCA3 gene and / or the PSA gene; a mixture, formed by the covalent bonding of the probe and microsphere, is hybridized with a reverse transcription P CR amplification product, after streptavidin phycoerythrin is added fluorescent signals of different microspheres can be detected to determine whether a sample to be detected contains the PCA3 and PSA genes and the expression condition thereof, and simultaneously, the PCA3 / PSA ratio can be obtained. The liquid-phase chip method and the reagent kit have the advantages of high sensitivity, high throughput, quick and accurate detection and the like, and can perform qualitative and quantitative detection on the PCA3 and PSA genes related to different degrees of prostate diseases including prostate cancer and benign prostatic hyperplasia and perform specific diagnosison the prostate cancer.

The invention discloses a method for preparing ice cream by adopting camel milk. According to the method disclosed by the invention, the camel milk or camel milk powder is used as the main raw material, then the raw materials such as honey, poria cocos, Chinese yam and sodium caseinate are added, a special raw material extraction technology is adopted, and the prepared ice cream is low in energy, high in protein content and low in fat content; meanwhile, due to the combined action of all raw materials, an adjuvant therapy effect on hyperlipidemia, hypertension, chronic pharyngitis, prostate disease, fatty liver and tumor radio-chemotherapy is obtained, congestive heart failure can also be relieved, coughs can be relieved, the kidney can be protected, negative conversion of hepatitis B is facilitated, and the immunity can be greatly enhanced.

A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS190 and transcribed from prostate tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS190-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS190 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.

A dietary supplement for treating or preventing prostate disease and / or vascular disease including saw palmetto, d-alpha tocopherol, d-gamma tocopherol, d-delta tocopherol, d-beta tocopherol, selenium, lycopene, zinc, folic acid, vitamin B12, and vitamin B6, each in a therapeutically effective amount.

A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to the prostate-specific antigen, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to homeopathic technology. In order to obtain the antibodies, the prostate-specific antigen isolated from the prostatic tissues of cattle or prepared synthetically is employed; a mixture of various, mostly centesimal, homeopathic dilutions is used. The method of treating diseases of the urogenital sphere consists in using activated forms of ultra-low doses of antibodies to prostate-specific antigen prepared by multiple consecutive dilutions and exposure to external factors.

The invention discloses an urtica open-loop lignan glycoside D serving as a 5alpha-reductase inhibitor, a preparation method thereof and use thereof. The urtica open-loop lignan glycoside D is prepared by using the underground part of urtica triangularis as a raw material, extracting the raw material with alcohol, mixing an alcohol extract with hot water to obtain a suspension, extracting the extract with petroleum ether, ethyl acetate and water-saturated n-butyl alcohol, separating the extract from a raffinate water layer with macroporous resin, eluting the extract and separating and purifying the extract by silica gel column chromatography. The urtica open-loop lignan glycoside D can obviously inhibit the generation of DHT and has the potential to be used to prevent and treat prostate diseases like finasteride which is a masculine medicament. The open-loop lignan glycoside raw material is pure natural vegetable roots and safe and readily available. The method is simple and easy to operate and avoids introducing toxic materials. The urtica open-loop lignan glycoside D is low in cost, has a remarkable effect in spite of a vegetable source and has a great significance for the researches on and development of anti-benign prostatic hyperplasia medicaments.

The invention provides a truffle hydrophilic solvent extractive and a drug, food and the health food thereof containing the truffle hydrophilic solvent extractive. The preparation method of the truffle hydrophilic solvent extractive includes the step that a hydrophilic solvent is used for extracting truffle, and the truffle hydrophilic solvent extractive includes ergosterol and the fat type and has an obvious ultraviolet absorption at 195 to 220nm wavelength position. The invention also provides the application in preparing the drug for curing prostate disease, male sexual disorder and low immunizing power of a human body or the food or the health food for improving the associative function thereof by taking the extractive of the truffle in a hydrophilic solvent as the active ingredient.

The present invention relates to a composite preparation containing phospholipid, alpha-linolenic acid, gamma-linolenic acid, tomato extract, phytosterol, etc. The composite preparation can be used to prepare health food, medicine and functional food that have the functions of treatment and prevention to cardiovascular diseases and prostate diseases, the alleviation of age-related awareness decrudescence, the improvement of memory, the relief of cerebral fatigue, the alleviation of mental pressure, and the improvement of childhood hyperkinetic syndrome. The composite preparation can be prepared into dosage forms of soft capsules, dropping pills, etc. which are convenient in administration and easy to popularization.

A medical device for treating prostatoplasia and prostatic cancer via urethra by photodynamic therapy is composed of the light source or power supply unit with laser, LED, or other light sources, a catheter with light emitting probe in it for correctly locating it at the prostate gland position, and a temp control system with temp sensor and temp monitoring and controlling instrument. Its manufacture is also disclosed.

The invention is a Chinese medicinal capsule to cure prostate disease. Its main raw material: 13 pure Chinese medicines such as Smilax glabra roxb, Rhizoma Dioscoreae Hypoglaueae, Amur Cork-tree Bark, Hedyotis diffusa Willd, ginseng, earth-worm, Common Cnidium Fruit, etc. It has functions of promoting blood circulation and removing blood stasis, clearing and detoxifying, benefiting Qi and nourishing kidney.

A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and / or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.